Yau T, et al. Checkmate 459: a randomized, multi-center phase 3 study of nivolumab (nivo) vs sorafenib (sor) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (AHCC). Abstract LBA38_PR. ESMO Congress 2019, 28 sept. Barcelona, Spanje.
Poly (ADP-ribose) polymerase (PARP-)remmers bij het ovariumcarcinoom
sep 2018 | Gynaecologische oncologie